Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

Radient will not merge into anything.

An entity wanting to manufacture and sell onko-sure can license it as UNI did. That entity has no reason to take on Radient's debt.

The only possible reason to merge with Radient is to use Radient as a tax loss.... but the IRS has cracked down on that little scheme. There are limits to the amount of losses the takeover entity can use, and it won't be enough to counter the lender debt.

Unfortunately, the problem with licensing onko-sure now is: UNI has Asia sales, and Asia was the only place onko-sure generated even modest revenues. This lack of future Asia revenues is just one more reason for an entity to NOT want to merge with Radient. Revenues outside Asia have always been negligible and there is no logical reason to assume revenues will ever be anything BUT negligible.

Onko-sure is a failure because the global medical community does not want to support it or prescribe it. It is that simple.